Published

Psilocybin may be effective for treatment-resistant depression

The largest trial to date of the psychedelic drug psilocybin has shown that, alongside psychological support, a single 25mg dose may improve the symptoms of treatment-resistant depression. The phase II study, published in the New England Journal of Medicine on 3 November 2022, was conducted across 22 sites in 10 countries, including the UK, between […]

Open source BibTeX RIS

Bibliographic context

Journal: Pharmaceutical journal/The pharmaceutical journal
Date: 2021-12-31
Source: OpenAlex
DOI: 10.1211/pj.2022.1.164911
PubMed: Unavailable

Authors

Watch author

Topics and keywords

psilocybin Depression Clinical Trial Treatment-Resistant Depression Clinical Trial Psilocybin Depression (economics)Treatment-resistant depression Psychiatry Medicine Psychology Psychotherapist Hallucinogen Major depressive disorder Keynesian economics Economics Cognition Psychedelics and Drug Studies Digital Mental Health Interventions

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin may be effective for treatment-resistant depression2021-12-31

Related papers

The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trialNeuroscience Applied · 2021-12-31 Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic PotentialDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21 The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidenceZenodo (CERN European Organization for Nuclear Research) · 2026-01-25 Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybinMed · 2024-02-13 Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-26 Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trialJournal of Affective Disorders · 2026-02-15 THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERSInternational Journal of Innovative Technologies in Social Science · 2026-01-22 Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic ReviewOpen Science Framework · 2025-12-31